The new Acyl-CoA cholesterol acyltransferase inhibitor SMP-797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 9, 2007, Pages 517-525

  Kitamura, Atsushi ^a   Imai, Satoki ^a   Yabuki, Masashi ^a   Komuro, Setsuko ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Inhibition; OATP1B1; SMP 797; Statins; Transporter

Indexed keywords

CARBON 14; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CYCLOSPORIN A; ESTRONE SULFATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N (4 AMINO 2,6 DIISOPROPYLPHENYL) N' [1 BUTYL 4 [3 (3 HYDROXYPROPOXY)PHENYL] 2 OXO 1,2 DIHYDRO 1,8 NAPHTHYRIDIN 3 YL]UREA; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B1; PRAVASTATIN; ROSUVASTATIN; SMP 797; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CRYOPRESERVATION; DRUG BINDING SITE; DRUG INHIBITION; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; NONHUMAN; OOCYTE;

BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT, ACTIVE; CRYOPRESERVATION; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ESTRONE; FLUOROBENZENES; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NAPHTHYRIDINES; OOCYTES; ORGANIC ANION TRANSPORTERS; PRAVASTATIN; PYRIMIDINES; SULFONAMIDES;

EID: 38849099654     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.581     Document Type: Article

References (23)

1. Ioriya K, Kino K, Horisawa S, et al. Pharmacological profile of SMP-797, a novel acyl-coenzyme A: cholesterol acyltransferase inhibitor with inducible effect on the expression of low-density lipoprotein receptor. J Cardiovasc Pharmacol 2006; 47: 322-329.
2. Bocan TMA, Mueller SB, Uhlendorf PD. Inhibition of acylCoA cholesterol O-acyltransferase reduces the cholesteryl ester enrichment of atherosclerotic lesions in the Yucatan micropig. Atherosclerosis 1993; 99: 175-186.
3. Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, Fisher EA. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2604-2609.
4. Wilcox LJ, Barrett PH, Newton RS, Huff MW. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of apoB. Arterioscler Thromb Vasc Biol 1999; 19: 939-949.
5. Taghibiglou C, Van Iderstine S, Kulinski A, Rudy D, Adeli K. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acylcoenzyme A:cholesterol acyltransferase (ACAT) inhibitor. Biochem Pharmacol 2002; 63: 349-360.
6. Delsing DJ, Offerman EH, van Duyvenvoorde W, et al. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 2001; 103: 1778-1786.
7. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011, is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998; 137: 77-85.
8. Bocan TM, Krause BR, Rosebury WS, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000; 20: 70-79.
9. Scharnagl H, Marz W. New lipid-lowering agents acting on LDL receptors. Curr Top Med Chem 2005; 5: 233-242.
10. -1. Am J Cardiol 1997; 79: 38-42.
11. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-425.
12. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581.
13. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007; 24: 239-247.
14. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304: 610-616.
15. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporin. Clin Pharmacol Ther 2004; 76: 167-177.
16. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-146.
17. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 2001; 18: 1262-1269.
18. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002; 30: 1158-1163.
19. Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297: 861-867.
20. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274: 37161-37168.
21. Brown CDA, Windass A, Bleasby K, Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atherosclerosis Suppl 2001; 2: 90.
22. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455-463.
23. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005; 33: 537-546.